{"database": "lobbying", "table": "lobbying_activities", "rows": [[2634854, "6e91c212-04f3-4999-a98a-3b55bf3d7fe7", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "GALEPHAR PHARMACEUTICAL RESEARCH INC.", 2021, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to the Food and Drug Administrations Pre-Approval of Supplemental through New Drug Application (NDA).", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-07-10T07:10:54.357000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2634854"], "units": {}, "query_ms": 14.841874013654888, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}